^
    3d
    Topical Diclofenac for Prevention of Radiation-induced Dermatitis (clinicaltrials.gov)
    P=N/A, N=156, Recruiting, The Second Affiliated Hospital of Hainan Medical University | Trial completion date: Dec 2026 --> Aug 2026 | Trial primary completion date: Dec 2025 --> Jun 2026
    Trial completion date • Trial primary completion date
    |
    IL4 (Interleukin 4)
    4d
    NCI-2022-03805: BALSTILIMAB on Viral Clearance in HPV+ Oropharyngeal Cancer Patients (clinicaltrials.gov)
    P2, N=20, Active, not recruiting, M.D. Anderson Cancer Center | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    balstilimab (AGEN2034)
    5d
    ILLUMINE: Study Comparing Ivonescimab Alone or Ivonescimab in Combination With Ligufalimab Versus Pembrolizumab for the Treatment of SCCHN (clinicaltrials.gov)
    P3, N=780, Not yet recruiting, Groupe Oncologie Radiotherapie Tete et Cou
    Trial initiation date
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • Yidafan (ivonescimab) • ligufalimab (AK117)
    6d
    Preventive Human Papillomavirus (HPV) Vaccine Trial in Kidney Transplant Recipients (clinicaltrials.gov)
    P2, N=51, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Mar 2026 --> Mar 2027
    Trial completion date
    |
    Gardasil 9 (human papillomavirus 9-valent vaccine, recombinant)
    6d
    BD4QoL: Big Data for Quality of Life in Head and Neck Cancer (clinicaltrials.gov)
    P=N/A, N=410, Completed, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | Recruiting --> Completed | Trial completion date: Jun 2025 --> Oct 2025 | Trial primary completion date: Sep 2024 --> Oct 2025
    Trial completion • Trial completion date • Trial primary completion date • HEOR
    6d
    NCI-2022-02855: Biomarker-Driven Radiation Therapy Dose Reduction After Transoral Robotic Surgery for the Treatment of HPV-Positive Oropharyngeal Cancer (clinicaltrials.gov)
    P2, N=33, Active, not recruiting, Emory University | Trial completion date: May 2026 --> Jan 2028
    Trial completion date
    6d
    Human Papillomavirus (HPV) Infected Epithelial Cells and FBLN1+ Fibroreticular Cells Govern the Immunogenic Tumor Microenvironment in HPV-Associated Oropharyngeal Squamous Cell Carcinoma. (PubMed, Clin Exp Otorhinolaryngol)
    Enhanced antigen presentation and epithelial proliferation likely facilitate tumor-immune interactions, contributing to better clinical outcomes. This study advances the understanding of TME dynamics in OPSCC and may inform future therapeutic strategies.
    Journal
    |
    SLIT2 (Slit Guidance Ligand 2)
    7d
    EXtRaCT study: Study of Xevinapant With Radiation and Chemotherapy for Patients With Head and Neck Cancer (clinicaltrials.gov)
    P1, N=42, Terminated, University of Chicago | Trial completion date: Oct 2027 --> May 2025 | Active, not recruiting --> Terminated | Trial primary completion date: Oct 2027 --> May 2025; Drug no longer being developed by manufacturer
    Trial completion date • Trial termination • Trial primary completion date
    |
    cisplatin • carboplatin • paclitaxel • xevinapant (Debio 1143)
    7d
    HexAgon-HN: INBRX-106 in Combination With Pembrolizumab in First-line PD-L1 CPS≥20 HNSCC (clinicaltrials.gov)
    P2/3, N=410, Active, not recruiting, Inhibrx Biosciences, Inc | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • ordastobart (INBRX-106)
    11d
    Biomarkers Associated With Extranodal Extension (ENE) in Oropharyngeal Squamous Cell Carcinoma (OPSCC): A Systematic Review. (PubMed, Head Neck)
    Multiple genomic and molecular biomarkers have been identified in association with ENE in OPSCC, suggesting that ENE is characterized by an EMT phenotype.
    Journal
    |
    ERBB3 (V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3) • NOTCH1 (Notch 1)
    13d
    SELECT-FR: SPECT-CT Guided ELEctive Contralateral Neck Treatment in Lateralized Oropharyngeal Cancer (clinicaltrials.gov)
    P=N/A, N=128, Not yet recruiting, UNICANCER | Initiation date: Jan 2026 --> Apr 2026
    Trial initiation date
    14d
    Adaptive De-intensified Radiotherapy Using Circulating Tumor DNA in HPV- Associated Oropharyngeal Cancer (clinicaltrials.gov)
    P2, N=45, Recruiting, Ohio State University Comprehensive Cancer Center | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial completion date • Trial primary completion date • Circulating tumor DNA
    |
    cisplatin • carboplatin • paclitaxel